Clinical experience with risperidone

Journal of Clinical Psychiatry

Volumn 57, Issue SUPPL. 9, 1996, Pages 57-61

  Marder, Stephen R ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PERPHENAZINE; RISPERIDONE;

CLINICAL TRIAL; CONFERENCE PAPER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MANIC DEPRESSIVE PSYCHOSIS; NEUROLEPTIC MALIGNANT SYNDROME; PRIAPISM; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SOMNOLENCE; TACHYCARDIA; VERTIGO; WEIGHT GAIN;

CLINICAL TRIALS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PSYCHOTIC DISORDERS; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0029816268     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (36)

1. Claus A, Bollen J, De Cuyper H, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand 1992;85:295-305
2. Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull 1992;28:213-218
3. Hoyberg OJ, Fensbo C, Remvig J, et al. Risperidone versus perphenazine in the treatment of chronic schizophrenic patients with acute exacerbations. Acta Psychiatr Scand 1993;88:395-402
4. Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry 1993;26:121-124
5. Heinrich K, Klieser E, Lehmann E, et al. Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double blind, randomized trial. Prog Neuropsychopharmacol Biol Psychiatry 1994;18:129-137
6. Min SK, Rhee CS, Kim CE, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J 1993;34:179-190
7. Muller-Spahn F, and The International Risperidone Research Group. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol [abstract]. CHn Neuropharmacol 1992; 15(suppl):90A-91A
8. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993; 13:25-40
9. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835
10. Davis JM. Risperidone: properties, use, efficacy, and side effects. Directions in Psychiatry 1994;14:1-7
11. Dwight MM, Keck PE Jr, Stanion SP, et al. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder [letter]. Lancet 1994;344:554-555
12. Tohen M, Zarate CA, Centorrino F, et al. Risperidone in the treatment of mania. Presented at the 33rd annual meeting of the American College of Neuropsychopharmacology; December 1994; San Juan, Puerto Rico
13. Goodnick PJ. Risperidone treatment of refractory acute mania [letter]. J Clin Psychiatry 1995;56:431-432
14. Meco G, Alessandria A, Bonifati V, et al. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients [letter]. Lancet 1994;343:1370-1371
15. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [reply to letter]. Lancet 1994;344:681
16. Stamenkovic M, Aschauer H, Kasper S. Risperidone for Tourelle's syndrome [letter]. Lancet 1994;344:1577-1578
17. van der Linden C, Bruggeman R, van Woerkom CS. Serotonin-dopamine antagonist and Gilles de la Tourette's Syndrome: an open pilot dose-titration study with risperidone [letter]. Mov Disord 1994; 9:687-688
18. Purdon SE, Lit W, Labelle A, et al. Risperidone in the treatment of pervasive developmental disorder. Can J Psychiatry 1994;39:400-405
19. Bressa GM, Bersani G, Meco G, et al. One year follow-up study with risperidone in chronic schizophrenia. New Trends in Experimental & Clinical Psychiatry 1991;7:169-177
20. Aldington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. Clin Ther 1993;15:917-926
21. Ernes CE, Millson RC. Risperidone-induced priapism [letter]. Can J Psychiatry 1994;39:315-316
22. Najara JE, Enikeev ID. Risperidone and neuroleptic malignant syndrome: a case report [letter]. J Clin Psychiatry 1995;56:534-535
23. Lee H, Ryan J, Mullett G, et al. Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent. Hum Psychopharmacol 1994;9:303-305
24. Raitasuo V, Vataja R, Elomaa E. Risperidone-induced neuroleptic malignant syndrome in young patient [letter]. Lancet 1994;344:1705
25. Webster P, Wijeratne C. Risperidone-induced neuroleptic malignant syndrome [letter]. Lancet 1994;344:1228-1229
26. Kopala L, Honer WG. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia [letter]. Am J Psychiatry 1994;151:1714-1715
27. Remington G, Adams M. Risperidone and obsessive-compulsive symptoms [letter]. J Clin Psychopharmacol 1994;14:358-359
28. Baker RW, Chengappa KNR, Baird JW, et al. Emergence of obsessive compulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992;53:439-442
29. Lacoursiere RB, Spohn HE, Thompson K. Medical effects of abrupt neuroleptic withdrawal. Compr Psychiatry 1976;17:285-294
30. Gardes G, Cole JO, Tarsy D. Withdrawal syndromes associated with anti-psychotic drugs. Am J Psychiatry 1978;135:1321-1324
31. Herson HI, Kennedy PF, McGuire RJ. Persistence of extrapyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. Br J Psychiatry 1972;120:41-50
32. Ekblom B, Eriksson K, Lindstrom LH. Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal. Psychopharmacology (Berl) 1984;83:293-294
33. Alphs LD, Lee HS. Comparison of withdrawal of typical and atypical anti-psychotic drugs: a case study. J Clin Psychiatry 1991;52:346-348
34. Parsa MA, al-Lahham YH, Ramirez JF, et al. Prolonged psychotic relapse after abrupt clozapine withdrawal [letter]. J Clin Psychopharmacol 1993; 13:154-155
35. Baldessarini RJ, Centorrino F, Flood JG, et al. Tissue concentrations of clozapine and its metabolites in the rat. Neuropsychopharmacology 1993; 9:117-124
36. Risperidone wins FDA approval, will compete with clozapine. Psychiatric News Feb 4, 1994;29:2